

# Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Research Report 2023

<https://marketpublishers.com/r/L617FFAF6A55EN.html>

Date: August 2023

Pages: 109

Price: US\$ 2,950.00 (Single User License)

ID: L617FFAF6A55EN

## Abstracts

Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

In this report, we only study liposomal/lipid nanoparticle drug delivery system.

LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).

In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.

## Highlights

The global Liposomal and Lipid Nanoparticle Drug Delivery Systems market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players

occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.

## Report Scope

This report aims to provide a comprehensive presentation of the global market for Liposomal and Lipid Nanoparticle Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal and Lipid Nanoparticle Drug Delivery Systems.

The Liposomal and Lipid Nanoparticle Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Liposomal and Lipid Nanoparticle Drug Delivery Systems companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

## Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to

the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

## Product Type Insights

Global markets are presented by Liposomal and Lipid Nanoparticle Drug Delivery Systems type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Liposomal and Lipid Nanoparticle Drug Delivery Systems are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

## Liposomal and Lipid Nanoparticle Drug Delivery Systems segment by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

## Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Liposomal and Lipid Nanoparticle Drug Delivery Systems market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Liposomal and Lipid Nanoparticle Drug Delivery Systems market.

## Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Application

Hospital

Retail Pharmacy

Other

## Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

### North America

United States

Canada

### Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Liposomal and Lipid Nanoparticle Drug Delivery Systems market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

## Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid Nanoparticle Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest

developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Liposomal and Lipid Nanoparticle Drug Delivery Systems industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid Nanoparticle Drug Delivery Systems.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Liposomal and Lipid Nanoparticle Drug Delivery Systems companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.



Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

## Contents

### **1 PREFACE**

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

### **2 MARKET OVERVIEW**

- 2.1 Product Definition
- 2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems by Type
  - 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
  - 2.2.2 Liposomes Drugs
  - 2.2.3 Lipid Nanoparticle Drugs
- 2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems by Application
  - 2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
  - 2.3.2 Hospital
  - 2.3.3 Retail Pharmacy
  - 2.3.4 Other
- 2.4 Assumptions and Limitations

### **3 LIPOSOMAL AND LIPID NANOPARTICLE DRUG DELIVERY SYSTEMS BREAKDOWN DATA BY TYPE**

- 3.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Type (2018-2023)
- 3.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2023-2028)

### **4 LIPOSOMAL AND LIPID NANOPARTICLE DRUG DELIVERY SYSTEMS BREAKDOWN DATA BY APPLICATION**

- 4.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Application (2018-2023)

4.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2018-2023)

## **5 GLOBAL GROWTH TRENDS**

5.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Perspective (2018-2029)

5.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Growth Trends by Region

5.2.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region: 2018 VS 2022 VS 2029

5.2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Region (2018-2023)

5.2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2024-2029)

5.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Dynamics

5.3.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Trends

5.3.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Drivers

5.3.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Challenges

5.3.4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Restraints

## **6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS**

6.1 Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Players by Revenue

6.1.1 Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Players by Revenue (2018-2023)

6.1.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2018-2023)

6.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Players Ranking, 2021 VS 2022 VS 2023

6.3 Global Key Players of Liposomal and Lipid Nanoparticle Drug Delivery Systems Head office and Area Served

6.4 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Product Type & Application

6.5 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Date of Enter into This Industry

6.6 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market CR5 and HHI

## 6.7 Global Players Mergers & Acquisition

## **7 NORTH AMERICA**

7.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)

7.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)

7.4 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)

7.5 United States

7.6 Canada

## **8 EUROPE**

8.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)

8.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029

8.3 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)

8.4 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

## **9 ASIA-PACIFIC**

9.1 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)

9.2 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size

by Country (2018-2023)

9.4 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size

by Country (2024-2029)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

## **10 LATIN AMERICA**

10.1 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)

10.2 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)

10.4 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)

9.4 Mexico

9.5 Brazil

## **11 MIDDLE EAST & AFRICA**

11.1 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)

11.2 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029

11.3 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)

11.4 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

## **12 PLAYERS PROFILED**

## 11.1 Johnson & Johnson

11.1.1 Johnson & Johnson Company Detail

11.1.2 Johnson & Johnson Business Overview

11.1.3 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems

Introduction

11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.1.5 Johnson & Johnson Recent Development

## 11.2 Sun Pharmaceutical

11.2.1 Sun Pharmaceutical Company Detail

11.2.2 Sun Pharmaceutical Business Overview

11.2.3 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems

Introduction

11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.2.5 Sun Pharmaceutical Recent Development

## 11.3 CSPC

11.3.1 CSPC Company Detail

11.3.2 CSPC Business Overview

11.3.3 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.3.4 CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.3.5 CSPC Recent Development

## 11.4 Kinyond

11.4.1 Kinyond Company Detail

11.4.2 Kinyond Business Overview

11.4.3 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.4.4 Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.4.5 Kinyond Recent Development

## 11.5 Teva

11.5.1 Teva Company Detail

11.5.2 Teva Business Overview

11.5.3 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.5.4 Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.5.5 Teva Recent Development

## 11.6 Fudan-Zhangjiang

11.6.1 Fudan-Zhangjiang Company Detail

11.6.2 Fudan-Zhangjiang Business Overview

11.6.3 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems

Introduction

11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.6.5 Fudan-Zhangjiang Recent Development

11.7 Zydus Cadila

11.7.1 Zydus Cadila Company Detail

11.7.2 Zydus Cadila Business Overview

11.7.3 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems

Introduction

11.7.4 Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.7.5 Zydus Cadila Recent Development

11.8 TTY Biopharma

11.8.1 TTY Biopharma Company Detail

11.8.2 TTY Biopharma Business Overview

11.8.3 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems

Introduction

11.8.4 TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.8.5 TTY Biopharma Recent Development

11.9 Pacira

11.9.1 Pacira Company Detail

11.9.2 Pacira Business Overview

11.9.3 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.9.4 Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.9.5 Pacira Recent Development

11.10 Luye Pharma

11.10.1 Luye Pharma Company Detail

11.10.2 Luye Pharma Business Overview

11.10.3 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems

Introduction

11.10.4 Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.10.5 Luye Pharma Recent Development

11.11 Leadiant Biosciences

11.11.1 Leadiant Biosciences Company Detail

- 11.11.2 Leadiant Biosciences Business Overview
- 11.11.3 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
- 11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
- 11.11.5 Leadiant Biosciences Recent Development
- 11.12 Ipsen
  - 11.12.1 Ipsen Company Detail
  - 11.12.2 Ipsen Business Overview
  - 11.12.3 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
  - 11.12.4 Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
  - 11.12.5 Ipsen Recent Development
- 11.13 Sayre Therapeutics
  - 11.13.1 Sayre Therapeutics Company Detail
  - 11.13.2 Sayre Therapeutics Business Overview
  - 11.13.3 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
  - 11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
  - 11.13.5 Sayre Therapeutics Recent Development
- 11.14 Jazz
  - 11.14.1 Jazz Company Detail
  - 11.14.2 Jazz Business Overview
  - 11.14.3 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
  - 11.14.4 Jazz Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
  - 11.14.5 Jazz Recent Development
- 11.15 Alnylam
  - 11.15.1 Alnylam Company Detail
  - 11.15.2 Alnylam Business Overview
  - 11.15.3 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
  - 11.15.4 Alnylam Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
  - 11.15.5 Alnylam Recent Development
- 11.16 Bausch Health
  - 11.16.1 Bausch Health Company Detail
  - 11.16.2 Bausch Health Business Overview
  - 11.16.3 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems



## Introduction

11.16.4 Bausch Health Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.16.5 Bausch Health Recent Development

## 11.17 Acrotech Biopharma

11.17.1 Acrotech Biopharma Company Detail

11.17.2 Acrotech Biopharma Business Overview

11.17.3 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems

## Introduction

11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.17.5 Acrotech Biopharma Recent Development

## 11.18 Takeda

11.18.1 Takeda Company Detail

11.18.2 Takeda Business Overview

11.18.3 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.18.4 Takeda Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.18.5 Takeda Recent Development

## 11.19 Chiesi Farmaceutici

11.19.1 Chiesi Farmaceutici Company Detail

11.19.2 Chiesi Farmaceutici Business Overview

11.19.3 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems

## Introduction

11.19.4 Chiesi Farmaceutici Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.19.5 Chiesi Farmaceutici Recent Development

## 11.20 Gilead Sciences

11.20.1 Gilead Sciences Company Detail

11.20.2 Gilead Sciences Business Overview

11.20.3 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems

## Introduction

11.20.4 Gilead Sciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.20.5 Gilead Sciences Recent Development

## **13 REPORT CONCLUSION**

## 14 DISCLAIMER

## List Of Tables

### LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2018-2023)

Table 7. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2024-2029)

Table 9. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2018-2023) & (US\$ Million)

Table 10. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2018-2023)

Table 11. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 12. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2024-2029)

Table 13. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region (2018-2023)

Table 16. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region (2024-2029)

Table 18. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Trends

Table 19. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Drivers

Table 20. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Challenges

Table 21. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Restraints

Table 22. Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of Liposomal and Lipid Nanoparticle Drug Delivery Systems, Headquarters and Area Served

Table 26. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Manufacturers, Product Type & Application

Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 28. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US\$ Million)

Table 32. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US\$ Million)

Table 33. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 34. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US\$ Million)

Table 35. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 37. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 40. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems

Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Johnson & Johnson Company Detail

Table 46. Johnson & Johnson Business Overview

Table 47. Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 48. Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 49. Johnson & Johnson Recent Development

Table 50. Sun Pharmaceutical Company Detail

Table 51. Sun Pharmaceutical Business Overview

Table 52. Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 53. Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 54. Sun Pharmaceutical Recent Development

Table 55. CSPC Company Detail

Table 56. CSPC Business Overview

Table 57. CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 58. CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 59. CSPC Recent Development

Table 60. Kinyond Company Detail

Table 61. Kinyond Business Overview

Table 62. Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 63. Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 64. Kinyond Recent Development

Table 65. Teva Company Detail

Table 66. Teva Business Overview

Table 67. Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 68. Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 69. Teva Recent Development

Table 70. Fudan-Zhangjiang Company Detail

Table 71. Fudan-Zhangjiang Business Overview

Table 72. Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 73. Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 74. Fudan-Zhangjiang Recent Development

Table 75. Zydus Cadila Company Detail

Table 76. Zydus Cadila Business Overview

Table 77. Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 78. Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 79. Zydus Cadila Recent Development

Table 80. TTY Biopharma Company Detail

Table 81. TTY Biopharma Business Overview

Table 82. TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 83. TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 84. TTY Biopharma Recent Development

Table 85. Pacira Company Detail

Table 86. Pacira Business Overview

Table 87. Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 88. Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 89. Pacira Recent Development

Table 90. Luye Pharma Company Detail

Table 91. Luye Pharma Business Overview

Table 92. Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 93. Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 94. Luye Pharma Recent Development

Table 95. Leadiant Biosciences Company Detail

Table 96. Leadiant Biosciences Business Overview

Table 97. Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product

Table 98. Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)

Table 99. Leadiant Biosciences Recent Development

- Table 100. Ipsen Company Detail
- Table 101. Ipsen Business Overview
- Table 102. Ipsen Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 103. Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 104. Ipsen Recent Development
- Table 105. Sayre Therapeutics Company Detail
- Table 106. Sayre Therapeutics Business Overview
- Table 107. Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 108. Sayre Therapeutics Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 109. Sayre Therapeutics Recent Development
- Table 110. Jazz Company Detail
- Table 111. Jazz Business Overview
- Table 112. Jazz Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 113. Jazz Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 114. Jazz Recent Development
- Table 115. Alnylam Company Detail
- Table 116. Alnylam Business Overview
- Table 117. Alnylam Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 118. Alnylam Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 119. Alnylam Recent Development
- Table 120. Bausch Health Company Detail
- Table 121. Bausch Health Business Overview
- Table 122. Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 123. Bausch Health Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 124. Bausch Health Recent Development
- Table 125. Acrotech Biopharma Company Detail
- Table 126. Acrotech Biopharma Business Overview
- Table 127. Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 128. Acrotech Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 129. Acrotech Biopharma Recent Development

- Table 130. Takeda Company Detail
- Table 131. Takeda Business Overview
- Table 132. Takeda Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 133. Takeda Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 134. Takeda Recent Development
- Table 135. Chiesi Farmaceutici Company Detail
- Table 136. Chiesi Farmaceutici Business Overview
- Table 137. Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 138. Chiesi Farmaceutici Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 139. Chiesi Farmaceutici Recent Development
- Table 140. Gilead Sciences Company Detail
- Table 141. Gilead Sciences Business Overview
- Table 142. Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
- Table 143. Gilead Sciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US\$ Million)
- Table 144. Gilead Sciences Recent Development
- Table 145. Johnson & Johnson Company Information
- Table 146. Johnson & Johnson Business Overview
- Table 147. Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)
- Table 148. Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio
- Table 149. Johnson & Johnson Recent Development
- Table 150. Sun Pharmaceutical Company Information
- Table 151. Sun Pharmaceutical Business Overview
- Table 152. Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)
- Table 153. Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio
- Table 154. Sun Pharmaceutical Recent Development
- Table 155. CSPC Company Information
- Table 156. CSPC Business Overview
- Table 157. CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in



Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 158. CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 159. CSPC Recent Development

Table 160. Kinyond Company Information

Table 161. Kinyond Business Overview

Table 162. Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 163. Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 164. Kinyond Recent Development

Table 165. Teva Company Information

Table 166. Teva Business Overview

Table 167. Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 168. Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 169. Teva Recent Development

Table 170. Fudan-Zhangjiang Company Information

Table 171. Fudan-Zhangjiang Business Overview

Table 172. Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 173. Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 174. Fudan-Zhangjiang Recent Development

Table 175. Zydus Cadila Company Information

Table 176. Zydus Cadila Business Overview

Table 177. Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 178. Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 179. Zydus Cadila Recent Development

Table 180. TTY Biopharma Company Information

Table 181. TTY Biopharma Business Overview

Table 182. TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 183. TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 184. TTY Biopharma Recent Development

Table 185. Pacira Company Information

Table 186. Pacira Business Overview

Table 187. Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 188. Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 189. Pacira Recent Development

Table 190. Luye Pharma Company Information

Table 191. Luye Pharma Business Overview

Table 192. Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 193. Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 194. Luye Pharma Recent Development

Table 195. Leadiant Biosciences Company Information

Table 196. Leadiant Biosciences Business Overview

Table 197. Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 198. Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 199. Leadiant Biosciences Recent Development

Table 200. Ipsen Company Information

Table 201. Ipsen Business Overview

Table 202. Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 203. Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 204. Ipsen Recent Development

Table 205. Sayre Therapeutics Company Information

Table 206. Sayre Therapeutics Business Overview

Table 207. Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 208. Sayre Therapeutics Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 209. Sayre Therapeutics Recent Development

Table 210. Jazz Company Information

Table 211. Jazz Business Overview

Table 212. Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 213. Jazz Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 214. Jazz Recent Development

Table 215. Alnylam Company Information

Table 216. Alnylam Business Overview

Table 217. Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 218. Alnylam Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 219. Alnylam Recent Development

Table 220. Bausch Health Company Information

Table 221. Bausch Health Business Overview

Table 222. Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 223. Bausch Health Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 224. Bausch Health Recent Development

Table 225. Acrotech Biopharma Company Information

Table 226. Acrotech Biopharma Business Overview

Table 227. Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)

Table 228. Acrotech Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio

Table 229. Acrotech Biopharma Recent Development

- Table 230. Takeda Company Information
- Table 231. Takeda Business Overview
- Table 232. Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)
- Table 233. Takeda Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio
- Table 234. Takeda Recent Development
- Table 235. Chiesi Farmaceutici Company Information
- Table 236. Chiesi Farmaceutici Business Overview
- Table 237. Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)
- Table 238. Chiesi Farmaceutici Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio
- Table 239. Chiesi Farmaceutici Recent Development
- Table 240. Gilead Sciences Company Information
- Table 241. Gilead Sciences Business Overview
- Table 242. Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million)
- Table 243. Gilead Sciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US\$ Million) Portfolio
- Table 244. Gilead Sciences Recent Development
- Table 245. Authors List of This Report

## List Of Figures

### LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Picture

Figure 5. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 6. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Type: 2022 VS 2029

Figure 7. Liposomes Drugs Product Picture

Figure 8. Lipid Nanoparticle Drugs Product Picture

Figure 9. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2023-2029) & (US\$ Million)

Figure 10. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Application: 2022 VS 2029

Figure 11. Hospital Product Picture

Figure 12. Retail Pharmacy Product Picture

Figure 13. Other Product Picture

Figure 14. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 15. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region: 2022 VS 2029

Figure 17. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Players in 2022

Figure 18. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Date of Enter into This Industry

Figure 19. Global Top 5 and 10 Liposomal and Lipid Nanoparticle Drug Delivery Systems Players Market Share by Revenue in 2022

Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 21. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Country (2018-2029)

Figure 23. United States Liposomal and Lipid Nanoparticle Drug Delivery Systems

Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Canada Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Country (2018-2029)

Figure 27. Germany Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. France Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. U.K. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Italy Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Russia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Nordic Countries Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Country (2018-2029)

Figure 35. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Japan Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. South Korea Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Southeast Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. India Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Australia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Country (2018-2029)

Figure 43. Mexico Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Brazil Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Country (2018-2029)

Figure 47. Turkey Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Saudi Arabia Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 49. UAE Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 50. Johnson & Johnson Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 51. Sun Pharmaceutical Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 52. CSPC Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 53. Kinyond Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 54. Teva Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 55. Fudan-Zhangjiang Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 56. Zydus Cadila Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 57. TTY Biopharma Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 58. Pacira Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 59. Luye Pharma Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 60. Leadiant Biosciences Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 61. Ipsen Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 62. Sayre Therapeutics Revenue Growth Rate in Liposomal and Lipid

Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 63. Jazz Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 64. Alnylam Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 65. Bausch Health Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 66. Acrotech Biopharma Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 67. Takeda Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 68. Chiesi Farmaceutici Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)

Figure 69. Gilead Sciences Revenue Growth Rate in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023)



## I would like to order

Product name: Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Research Report 2023

Product link: <https://marketpublishers.com/r/L617FFAF6A55EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L617FFAF6A55EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970